AbbVie will announce its third-quarter 2026 financial results on October 30, 2026, before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. This event is important for investors to assess AbbVie's performance in key therapeutic areas like immunology, neuroscience, and oncology. An archived version of the call will be available later the same day for those who cannot attend live.
As of Oct 01, 2026 19:14 WIB, AbbVie Inc (ABBV) shares are trading at USD 260.68 on Pluang, showing a slight 0.42% decline in the last day. The stock's market capitalization stands at $462.26 billion, with a dividend yield of 2.65%. Investor interest remains strong with 77% of Pluang order activity favoring buys, highlighting continued confidence ahead of the upcoming third-quarter earnings call scheduled for October 30, 2026.
Bank of America increased price targets for AbbVie to $289 and Johnson & Johnson to $278, maintaining Buy and Neutral ratings respectively. AbbVie is favored due to its strong growth potential, robust pipeline, and attractive valuation at 16 times fo...
AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing meaningful weight loss of up to 9.8% over 12-13 weeks with weekly, biweekly, and monthly dosing options. The drug demonstrated a half-l...
AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch...
AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress, showcasing new data on its dermatology portfolio including approved drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ), as well as investigational...
AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug devel...
